Eyepoint Pharmaceuticals Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Watertown MA United States (1987)
Status: No NME R&D (1987)

Organization Overview

First Clinical Trial
2008
NCT00605423
First Marketed Drug
2018
dexamethasone
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

EyePoint Pharmaceuticals, Inc. | EYEPOINT PHARMS | pSivida Corp. | pSiVida Limited